RIPK1 and cancer: In recent years, immunotherapy has shown significant antitumor efficacy, and future research could focus on the development of novel drugs or combination strategies that can induce PANoptosis in cancer cells by mediating RIPK1, caspase-8, caspase-3, MLKL and other pathways to kill tumor cells and reverse the unfavorable TME.